Loading...

Sionna Therapeutics, Inc.

SION•NASDAQ
Healthcare
Biotechnology
$17.35
$0.00(0.00%)

Sionna Therapeutics, Inc. (SION) Stock Overview

Explore Sionna Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap801.3M
P/E Ratio-8.34
EPS (TTM)$-1.50
ROE2.97%
Fundamental Analysis

AI Price Forecasts

1 Week$15.22
1 Month$24.51
3 Months$4.01
1 Year TargetN/A

SION Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sionna Therapeutics, Inc. (SION) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.34 and a market capitalization of 801.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for SIONStats details for SION are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$45.00
Average$45.00
High$45.00

Company Profile

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

CEO

Michael Cloonan

Employees

41

Headquarters

21 Hickory Drive Suite 500, Waltham, MA

Founded

2025

Frequently Asked Questions

;